Search research articles
Contact Us
Filters
Showing results (81-90 of 126) with videos related to
Page
of 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study
Adnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
The Lancet. Oncology
|
August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
The New England Journal of Medicine
|
June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Matteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
Melanoma Research
|
September 27, 2022
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series
Jessica Louise Smith, Alexander M Menzies, Justine V Cohen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2022
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes
Joanna Lee, Tasnia Ahmed, Andrea Maurichi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.
The Lancet. Oncology
|
August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kicinski, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 126) with videos related to
Sort By:
Page
of 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study
Adnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
The Lancet. Oncology
|
August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
The New England Journal of Medicine
|
June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Matteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
Melanoma Research
|
September 27, 2022
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series
Jessica Louise Smith, Alexander M Menzies, Justine V Cohen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2022
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes
Joanna Lee, Tasnia Ahmed, Andrea Maurichi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.
The Lancet. Oncology
|
August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kicinski, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, et al.
Page
of 13